Human GBM surgical specimen slice cultures treated with 1.8 nM Ispinesib for 18 h showed depletion of a MES/AC signature and enrichment of cell cycle signatures, except in an outlier patient’s slice culture. In Panc1 cells, 10 nmol/L Ispinesib for 96 hours significantly increased multinucleation to 44.9%, compared with 4.1% in vehicle-treated cells. In TS543 cells, Ispinesib alone reached maximum efficacy at 25%–20% viability. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Ispinesib and transcriptional signatures in human glioblastoma slices
Cell-based study · slice cultures from human GBM surgical specimens [1]
Human GBM surgical specimen slice cultures received 1.8 nM Ispinesib for 18 h. Treatment depleted a MES/AC signature and enriched cell cycle signatures, except in an outlier patient’s slice culture.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1.8 nM
- Exposure duration
- 18 h
- Method
- the medium was replaced with pre-warmed medium containing drugs
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: Ispinesib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > Ispinesib-treated GBM patient slice cultures share phenotypic features with TS543 ispinesib-resistant phenotype (S41, S44); STAR★METHODS > METHOD DETAILS > Human glioma patient ex vivo tissue slices acute drug treatment (S120, S122); Figure 3. legend (S183)
scRNA-seq: scRNA-seq; comparator: corresponding volume of vehicle (DMSO) — RESULTS > Ispinesib-treated GBM patient slice cultures share phenotypic features with TS543 ispinesib-resistant phenotype (S41, S44); STAR★METHODS > METHOD DETAILS > Human glioma patient ex vivo tissue slices acute drug treatment (S120, S122)
Ispinesib and multinucleation in pancreatic cancer cells
Cell-based study · Panc1 cells [2]
Panc1 cells received 10 nmol/L Ispinesib for 96 hours. The proportion of multinucleated cells increased significantly to 44.9%, compared with 4.1% in DMSO vehicle-treated cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 nmol/L
- Exposure duration
- 96 hours
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Ispinesib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
MATERIALS AND METHODS > Immunofluorescence staining (S46); FIGURE 2 legend (S180, S182, S183)
proportion of multinucleated cells: proportion of multinucleated cells; comparator: DMSO vehicle‐treated cells — MATERIALS AND METHODS > Immunofluorescence staining (S46); FIGURE 2 legend (S182)
Ispinesib efficacy in a cell viability assay
Cell-based study · TS543 cells [1]
TS543 cells were treated with Ispinesib, and viability was assessed using PrestoBlue Cell Viability Reagent. Ispinesib alone reached maximum efficacy of 25%–20% viability.
Literature-Reported Treatment Conditions
- Exposure duration
- treated with inhibitor for three days
- Reported limits
- Not stated in the sentences used: dose, route, vehicle, control.
Methods and source locations
Compound reported in the paper: Ispinesib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > Identification of synergistic drug targets from gene expression analysis of ispinesib-resistant clones in the drug-naive setting (S84); STAR★METHODS > METHOD DETAILS > Dose response assays (S129, S130)
Cell viability was assessed with PrestoBlue Cell Viability Reagent: Cell viability was assessed with PrestoBlue Cell Viability Reagent — RESULTS > Identification of synergistic drug targets from gene expression analysis of ispinesib-resistant clones in the drug-naive setting (S84); STAR★METHODS > METHOD DETAILS > Dose response assays (S130)
